



Iroko Pharmaceuticals Inc. Files Registration Statement for Initial Public Offering

Philadelphia, Pennsylvania, June 18, 2013, Iroko Pharmaceuticals Inc. (www.iroko.com), announced today that it has filed a registration statement with the Securities and Exchange Commission for a proposed initial public offering of its ordinary shares. All ordinary shares proposed to be offered for sale will be offered by Iroko Pharmaceuticals. The number of ordinary shares and the price range for the proposed offering have not yet been determined. Iroko Pharmaceuticals plans to list its ordinary shares on the NASDAQ Global Select Market under the ticker symbol "IRKO."

Jefferies LLC and William Blair & Company, L.L.C. will act as joint book-running managers for the proposed offering and Canaccord Genuity Inc. will act as lead manager. The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus related to the offering may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY 10022, telephone: (877) 547-3640, or email: Prospectus_Department@Jefferies.com; William Blair & Company, L.L.C., Attention: Prospectus Department, 222 West Adams Street, Chicago, IL 60606, telephone: (800) 621-0687, or email: prospectus@williamblair.com; or Canaccord Genuity Inc., Attention: Syndicate Department, 99 High Street, 12th Floor, Boston, MA 02110, or telephone: (617) 371-3900.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Media Contact: Jessica Donnelly, for Iroko Pharmaceuticals Inc.
+1 212 798 9819 ; jessica.donnelly@cohnwolfe.com